# A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus

> **NCT01405885** · PHASE1 · COMPLETED · sponsor: **Inovio Pharmaceuticals** · enrollment: 116 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** INO-3605
- **BIOLOGICAL:** INO-3609
- **BIOLOGICAL:** INO-3401
- **BIOLOGICAL:** INO-3609
- **BIOLOGICAL:** INO-3605 AND INO-3609
- **BIOLOGICAL:** INO-3510
- **BIOLOGICAL:** INO-3609
- **BIOLOGICAL:** INO-3609
- **BIOLOGICAL:** Seasonal Influenza vaccine
- **BIOLOGICAL:** INO-3609

## Key facts

- **NCT ID:** NCT01405885
- **Lead sponsor:** Inovio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2014-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01405885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01405885, "A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01405885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*